{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:21:13Z","timestamp":1789730473357,"version":"4.0.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.dmd.2025.100056","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:11:55Z","timestamp":1741115515000},"page":"100056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-5488","authenticated-orcid":false,"given":"Mark A.","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5680-953X","authenticated-orcid":false,"given":"Riley","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-2651","authenticated-orcid":false,"given":"Chester","family":"Costales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-8746","authenticated-orcid":false,"given":"Sook Wah","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-6329","authenticated-orcid":false,"given":"Manthena V.S.","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100056_bib1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00228-014-1705-y","article-title":"Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers","volume":"70","author":"Akamine","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","article-title":"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers","volume":"72","author":"Allred","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2125.2005.02462.x","article-title":"Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin","volume":"60","author":"Ando","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative contribution of six major transporters to the hepatic uptake of drugs: \u201cSLC-phenotyping\u201d using primary human hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1208\/s12248-017-0051-2","article-title":"Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes","volume":"19","author":"Bi","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.dmd.2025.100056_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40261-020-00974-8","article-title":"Evaluation of pharmacokinetic drug interactions of the direct-acting antiviral agents elbasvir and grazoprevir with pitavastatin, rosuvastatin, pravastatin, and atorvastatin in healthy adults","volume":"41","author":"Caro","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.dmd.2025.100056_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.5414\/CP202412","article-title":"Pharmacokinetics of a telmisartan\/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects","volume":"53","author":"Chae","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1681\/ASN.20203110S1720c","article-title":"Pharmacokinetic evaluation of drug interactions between vadadustat and HMG-CoA reductase inhibitors (statins) P02368","volume":"31","author":"Chavan","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.dmd.2025.100056_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-003-0573-7","article-title":"The effect of erythromycin on the pharmacokinetics of rosuvastatin","volume":"59","author":"Cooper","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-002-0508-8","article-title":"The effect of fluconazole on the pharmacokinetics of rosuvastatin","volume":"58","author":"Cooper","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0009-9236(02)17633-8","article-title":"Effect of itraconazole on the pharmacokinetics of rosuvastatin","volume":"73","author":"Cooper","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10637-016-0353-8","article-title":"Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin","volume":"34","author":"Coss","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.dmd.2025.100056_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/psp4.12672","article-title":"Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling","volume":"10","author":"Costales","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib17","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/mp500330y","article-title":"Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine","volume":"11","author":"Drozdzik","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2025.100056_bib18","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12325-017-0601-0","article-title":"Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects","volume":"34","author":"Edwards","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug\u2013drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100056_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2019.104642","article-title":"Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): from library screening to biological evaluation to structure-activity relationship","volume":"61","author":"Fan","year":"2019","journal-title":"Toxicol In\u00a0Vitro"},{"key":"10.1016\/j.dmd.2025.100056_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1517\/13543784.2010.539559","article-title":"Aleglitazar, a balanced PPAR\u03b1\/\u03b3 agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin","volume":"20","author":"Foley-Comer","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.dmd.2025.100056_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.115.066712","article-title":"Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of irinotecan hydrochloride","volume":"44","author":"Fujita","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100056_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgad007","article-title":"Human monocarboxylate transporters accept and relay protons via the bound substrate for selectivity and activity at physiological pH","volume":"2","author":"Geistlinger","year":"2023","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.dmd.2025.100056_bib24","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1111\/bcp.14697","article-title":"Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: a phase I, multicentre, open-label, single-sequence drug-drug interaction study","volume":"87","author":"Grande","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00228-013-1592-7","article-title":"Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates","volume":"70","author":"Haberer","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1124\/mol.105.019547","article-title":"Functional analysis of the extracellular cysteine residues in the human organic anion transporting polypeptide, OATP2B1","volume":"70","author":"H\u00e4nggi","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13799","article-title":"Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters","volume":"17","author":"Ho","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmd.2025.100056_bib29","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00228-016-2130-1","article-title":"Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in\u00a0vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin","volume":"72","author":"Hu","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00228-016-2065-6","article-title":"No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects","volume":"72","author":"Huguet","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib32","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/0091270011408612","article-title":"Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose","volume":"52","author":"Ieiri","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32834300cc","article-title":"The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans","volume":"21","author":"Imanaga","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2025.100056_bib34","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1124\/dmd.110.034025","article-title":"Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice","volume":"38","author":"Jappar","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100056_bib35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcph.495","article-title":"Clinical drug interaction profile of idelalisib in healthy subjects","volume":"55","author":"Jin","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/dmd.116.072397","article-title":"Inhibition of intestinal OATP2B1 by the calcium receptor antagonist ronacaleret results in a significant drug-drug interaction by causing a 2-fold decrease in exposure of rosuvastatin","volume":"45","author":"Johnson","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100056_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpt.1599","article-title":"Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI","volume":"107","author":"Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib38","doi-asserted-by":"crossref","first-page":"992","DOI":"10.5414\/CP202615","article-title":"Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers","volume":"54","author":"Kang","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib39","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.dmd.2025.100056_bib40","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.xphs.2017.03.010","article-title":"Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP","volume":"106","author":"Kashihara","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100056_bib41","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.xphs.2017.04.001","article-title":"The organic anion-transporting peptide 2B1 is localized in the basolateral membrane of the human jejunum and Caco-2 monolayers","volume":"106","author":"Keiser","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100056_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/DDDT.S129586","article-title":"Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?","volume":"11","author":"Kim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib44","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2147\/DDDT.S130050","article-title":"Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers","volume":"11","author":"Kim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114534","article-title":"OATP2B1\u2014the underrated member of the organic anion transporting polypeptide family of drug transporters?","volume":"188","author":"Kinzi","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/jpet.103.051300","article-title":"Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane","volume":"306","author":"Kobayashi","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5414\/CP202275","article-title":"Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor","volume":"53","author":"Kulmatycki","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/17425255.2012.678048","article-title":"Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability\u2014considerations for drug development","volume":"8","author":"Lai","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2025.100056_bib49","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/dmd.114.062174","article-title":"Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design","volume":"43","author":"Lee","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100056_bib50","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.clinthera.2014.06.004","article-title":"Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study","volume":"36","author":"Lee","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cpt.3067","article-title":"Ticagrelor increases exposure to the breast cancer resistance protein substrate rosuvastatin","volume":"115","author":"Lehtisalo","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bcp.15485","article-title":"A\u00a0comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics","volume":"89","author":"Lehtisalo","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib53","doi-asserted-by":"crossref","first-page":"C570","DOI":"10.1152\/ajpcell.00436.2008","article-title":"Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters","volume":"296","author":"Leuthold","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.dmd.2025.100056_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40268-015-0120-x","article-title":"Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies","volume":"16","author":"Martin","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.dmd.2025.100056_bib55","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1124\/mol.110.069971","article-title":"Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3","volume":"79","author":"Martinez-Becerra","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pharmthera.2018.12.009","article-title":"Organic anion transporting polypeptide 2B1\u2014more than a glass-full of drug interactions","volume":"196","author":"McFeely","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40262-015-0334-7","article-title":"Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir","volume":"55","author":"Mogalian","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100056_bib58","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/cpdd.957","article-title":"Effect of upadacitinib on the pharmacokinetics of rosuvastatin or atorvastatin in healthy subjects","volume":"10","author":"Mohamed","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.dmd.2025.100056_bib59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jcph.1496","article-title":"Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: a study with the modified cooperstown 5+1 cocktail","volume":"60","author":"Mohamed","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.dmpk.2019.12.002","article-title":"pH-dependent transport kinetics of the human organic anion-transporting polypeptide 1A2","volume":"35","author":"Morita","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100056_bib61","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.103.060194","article-title":"Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human","volume":"308","author":"Nozawa","year":"2004","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pharmthera.2018.10.007","article-title":"Organic anion transporting polypeptide (OATP) transporter expression, localization and function in the human intestine","volume":"195","author":"Oswald","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib63","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1111\/bcp.14707","article-title":"Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP","volume":"87","author":"Ou","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1476-4598-12-47","article-title":"The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line","volume":"12","author":"Pagliarulo","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.dmd.2025.100056_bib65","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/jcph.1689","article-title":"Assessment of clinical drug-drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist","volume":"60","author":"Polepally","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101809","article-title":"Fevipiprant has a low risk of influencing co-medication pharmacokinetics: impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes","volume":"57","author":"Poller","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12377","article-title":"Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin","volume":"78","author":"Prueksaritanont","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cpt.525","article-title":"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A","volume":"101","author":"Prueksaritanont","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.726669","article-title":"Quantification of CYP3A and drug transporters activity in healthy young, healthy elderly and chronic kidney disease elderly patients by a microdose cocktail approach","volume":"12","author":"Rattanacheeworn","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib71","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.clinthera.2014.06.022","article-title":"Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects","volume":"36","author":"Roh","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib72","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib73","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s12325-019-00976-9","article-title":"Pharmacokinetic drug interactions between amlodipine, valsartan, and rosuvastatin in healthy volunteers","volume":"36","author":"Seong","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib74","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/FJC.0b013e31822b9092","article-title":"The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers","volume":"58","author":"Shin","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.dmd.2025.100056_bib75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmd.2025.100056_bib76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib77","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.clinthera.2014.06.007","article-title":"Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study","volume":"36","author":"Son","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmd.2025.100056_bib78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13318-017-0427-9","article-title":"Effects of metformin and furosemide on rosuvastatin pharmacokinetics in healthy volunteers: implications for their use as probe drugs in a transporter cocktail","volume":"43","author":"Stopfer","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100056_bib79","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1389200221666200620210522","article-title":"2020 FDA drug-drug interaction guidance: a comparison analysis and action plan by pharmaceutical industrial scientists","volume":"21","author":"Sudsakorn","year":"2020","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmd.2025.100056_bib80","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.110.032151","article-title":"Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation","volume":"38","author":"Sweeny","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100056_bib81","first-page":"488","article-title":"Clinically relevant OATP2B1 inhibitors in marketed drug space","volume":"17","author":"Unger","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2025.100056_bib82","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1021\/acs.analchem.0c02186","article-title":"Direct automated MALDI mass spectrometry analysis of cellular transporter function: inhibition of OATP2B1 uptake by 294 drugs","volume":"92","author":"Unger","year":"2020","journal-title":"Anal Chem"},{"key":"10.1016\/j.dmd.2025.100056_bib83","unstructured":"USFDA (2020) In\u00a0vitro drug interaction studies. Cytochrome P450 enzyme- andtransporter-mediated drug interactions. Guidance for industry. Draft Guidance Center for Drug Evaluation and Research (CDER). https:\/\/www.fda.gov\/media\/135587\/download"},{"key":"10.1016\/j.dmd.2025.100056_bib84","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/mp200103h","article-title":"pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1","volume":"8","author":"Varma","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2025.100056_bib85","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s40262-020-00907-w","article-title":"Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine","volume":"59","author":"Wiebe","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100056_bib86","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.xphs.2017.03.027","article-title":"Rosuvastatin pharmacokinetics in Asian and white subjects wild type for both OATP1B1 and BCRP under control and inhibited conditions","volume":"106","author":"Wu","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100056_bib87","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.xphs.2017.04.004","article-title":"Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings","volume":"106","author":"Yu","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100056_bib88","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in\u00a0vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625090658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625090658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:34:38Z","timestamp":1745562878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625090658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0090955625090658"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100056","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100056"}}